[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zentalis Pharmaceuticals Inc (ZNTL)

Zentalis Pharmaceuticals Inc (ZNTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 266,947
  • Shares Outstanding, K 71,186
  • Annual Sales, $ 0 K
  • Annual Income, $ -137,060 K
  • EBIT $ -137 M
  • EBITDA $ -139 M
  • 60-Month Beta 1.96
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.37

Options Overview Details

View History
  • Implied Volatility 402.40% (+188.63%)
  • Historical Volatility 66.16%
  • IV Percentile 90%
  • IV Rank 53.33%
  • IV High 664.07% on 10/14/25
  • IV Low 103.37% on 01/16/26
  • Expected Move (DTE 2) 0.04 (1.12%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 125
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 7,575
  • Open Int (30-Day) 7,239
  • Expected Range 3.74 to 3.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.47
  • Number of Estimates 3
  • High Estimate $-0.37
  • Low Estimate $-0.52
  • Prior Year $-0.37
  • Growth Rate Est. (year over year) -27.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.42 +10.53%
on 06/05/26
4.33 -12.70%
on 05/22/26
-0.27 (-6.67%)
since 05/15/26
3-Month
2.07 +82.61%
on 03/30/26
6.95 -45.61%
on 04/10/26
+1.07 (+39.48%)
since 03/13/26
52-Week
1.13 +234.51%
on 07/01/25
6.95 -45.61%
on 04/10/26
+2.44 (+182.09%)
since 06/13/25

Most Recent Stories

More News
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Zentalis ®  Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1...

ZNTL : 3.78 (+0.80%)
Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy

Appointments enhance commercialization readiness as Zentalis advances registrational program for azenosertib in Cyclin-E1 positive platinum-resistant ovarian cancer  SAN DIEGO, May 27, 2026 (GLOBE...

ZNTL : 3.78 (+0.80%)
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was observed with low frequency of high-grade adverse events Activity of the combined regimen...

ZNTL : 3.78 (+0.80%)
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Zentalis ®  Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor...

ZNTL : 3.78 (+0.80%)
Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

400mg QD 5:2 selected as azenosertib monotherapy pivotal study dose based on favorable benefit-risk profile in DENALI Part 2a, supporting advancement in registration-intended trials DENALI Phase 2 trial...

ZNTL : 3.78 (+0.80%)
A Breakout Year for WEE1? Oppenheimer Sees 6x Upside in This Under-the-Radar Biotech

Analysts have initiated bullish coverage of Aprea Therapeutics with price targets up to 6x current levels, citing the superior safety profile and $700M peak sales potential of its WEE1 inhibitor program...

AZN : 177.27 (-0.83%)
ZNTL : 3.78 (+0.80%)
ACRV : 1.5200 (+2.70%)
SDGR : 14.60 (+1.04%)
APRE : 0.6986 (+1.82%)
Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Global Phase 3, randomized, controlled trial comparing azenosertib to standard-of-care chemotherapy now enrolling ASPENOVA designed as confirmatory study to support DENALI Phase 2 accelerated approval...

ZNTL : 3.78 (+0.80%)
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Zentalis ®  Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor...

ZNTL : 3.78 (+0.80%)
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer

SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1...

ZNTL : 3.78 (+0.80%)
Zentalis Surges 20% on WEE1 Inhibitor Dose Selection—But Is Aprea the Real Winner in This Space?

While Zentalis’ dose selection marks a significant clinical milestone, the underlying data suggests that Aprea’s APR-1051 may offer a superior therapeutic profile by maintaining daily dosing

ZNTL : 3.78 (+0.80%)

Business Summary

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics targeting cancers. The company's lead programs consist of ZN-c5, an oral selective estrogen receptor degrader for estrogen-receptor-positive, HER2-negative...

See More

Key Turning Points

3rd Resistance Point 4.38
2nd Resistance Point 4.22
1st Resistance Point 4.00
Last Price 3.78
1st Support Level 3.62
2nd Support Level 3.46
3rd Support Level 3.24

See More

52-Week High 6.95
Fibonacci 61.8% 4.73
Fibonacci 50% 4.04
Last Price 3.78
Fibonacci 38.2% 3.35
52-Week Low 1.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.